Who are Fluciclovine PET/CT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fludeoxyglucose F 18 (FDG), [F-18]-Fludeoxyglucose, C-11 labeled nicotine, piflufolastat (18F), Flotufolastat (18F), 18F-rhPSMA-7.3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluciclovine-pet-ct.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fluciclovine PET/CT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluciclovine PET/CT (Fluciclovine PET/CT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Oncology.

marketed PET imaging agent Amino acid transporters (LAT1, ASCT2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fluciclovine PET/CT (Fluciclovine PET/CT) — OHSU Knight Cancer Institute. Fluciclovine is a fluorine-18 labeled amino acid analog that accumulates in cancer cells with high amino acid metabolism, enabling PET/CT imaging detection of malignant lesions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fluciclovine PET/CT TARGET	Fluciclovine PET/CT	OHSU Knight Cancer Institute	marketed	PET imaging agent	Amino acid transporters (LAT1, ASCT2)
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
[F-18]-Fludeoxyglucose	[F-18]-Fludeoxyglucose	University of Saskatchewan	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
C-11 labeled nicotine	C-11 labeled nicotine	University of Cincinnati	marketed	PET imaging agent / radiotracer	Nicotinic acetylcholine receptors
piflufolastat (18F)	piflufolastat (18F)	Blue Earth Diagnostics	marketed	PSMA-targeting PET imaging agent	PSMA (prostate-specific membrane antigen)
Flotufolastat (18F)	Flotufolastat (18F)	Blue Earth Diagnostics	marketed	Folate receptor-targeted PET imaging agent	Folate receptor alpha (FR-α)
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

University of California, San Francisco · 2 drugs in this class
Central Hospital, Nancy, France · 1 drug in this class
Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Institute for Neurodegenerative Disorders · 1 drug in this class
OHSU Knight Cancer Institute · 1 drug in this class
Piramal Imaging Limited · 1 drug in this class
SOFIE · 1 drug in this class
Universidad Central del Caribe · 1 drug in this class
University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluciclovine PET/CT — Competitive Intelligence Brief. https://druglandscape.com/ci/fluciclovine-pet-ct. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab